Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dtsch Med Wochenschr. 2012 Jan;137(4):138-41. doi: 10.1055/s-0031-1298816. Epub 2012 Jan 18.

[Apixaban: pharmacology and action profile].

[Article in German]

Author information

  • 1Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Germany. Natig.Gassanov@uk-koeln.de

Abstract

Vitamin K antagonists are currently the most frequently used anticoagulants. However, practical limitations of their application, such as variability in dose response, a narrow therapeutic index and numerous drug and dietary interactions, have lead to development of new oral anticoagulants with better efficacy and safety profile. Recent advances included the development of orally active FXa inhibitors rivaroxaban and apixaban. Rivaroxaban received its marketing approval in September 2008. Apixaban has recently been approved for prevention of venous thromboembolism after total hip or knee replacement. This review describes the pharmacological properties of apixaban and discusses the latest findings from clinical trials.

© Georg Thieme Verlag KG Stuttgart · New York.

PMID:
22259168
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk